QL1706 Combined With Standard Therapy for Conversion Therapy of Synchronous Liver Metastases From Colon Cancer: a Multicenter, Single-arm, Exploratory Study

NCT07649473 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Colon Cancer
Synchronous Liver Metastases

Interventions

DRUG: QL1706 (Iparomlimab/Tuvonralimab)

Sponsor

Fujian Medical University